Body mass index predicts ventricular repolarisation in obese children: differential effects across obesity levels

Metin Karayakalı1, Kayıhan Karaman1, Tuba Kasap2

  • 1Department of Cardiology, Tokat Gaziosmanpaşa University, Tokat, Turkey.

Insights

Childhood obesity is linked to abnormal heart repolarisation, even before metabolic issues arise. A body mass index (BMI) threshold can help identify children at risk for these early cardiac changes.

Area of Science:

  • Cardiology
  • Pediatrics
  • Biomedical Engineering

Background:

  • Childhood obesity is linked to cardiac electrical remodelling.
  • The specific relationship between body mass index (BMI) and ventricular repolarisation (VR) heterogeneity in paediatric obesity is not fully understood.

Purpose of the Study:

  • To investigate the association between BMI and VR heterogeneity in obese children.
  • To identify predictors and thresholds for abnormal repolarisation in paediatric obesity.

Main Methods:

  • Prospective observational study of 184 children (8-17 years; 112 obese, 72 normal-weight).
  • Electrocardiographic analysis included traditional (QT, QTc, JT) and novel VR parameters (Tp-e interval, Tp-e/QT, Tp-e/QTc ratios).
  • Multiple linear regression and ROC analyses were used to identify predictors and thresholds.

Main Results:

  • Obese children showed significantly prolonged Tp-e intervals and elevated Tp-e/QTcB ratios.
  • BMI was an independent predictor of VR heterogeneity, irrespective of metabolic or structural cardiac factors.
  • A BMI threshold of ≥ 23.1 kg/m² was identified for abnormal repolarisation (AUC = 0.682).

Conclusions:

  • Childhood obesity is associated with ventricular repolarisation abnormalities, independent of metabolic dysfunction or structural cardiac changes.
  • These repolarisation abnormalities appear early in obesity via distinct pathophysiological pathways.
  • A defined BMI threshold aids in early risk stratification for intervention.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...